Startup Funding Tracker — 2026-03-29

---

Top Deals

---

OpenAI — $10 Billion (Additional Disclosed Round)

• What they do: Developer of ChatGPT and foundational large language models
• Investors: Details not yet fully disclosed; round follows OpenAI's February $110B raise
• Why it matters: OpenAI's disclosure of yet another $10 billion capital raise this week signals the AI arms race is nowhere near cooling off. Coming just weeks after the $110B mega-round, this underscores the company's relentless appetite for compute and talent at a scale unmatched in startup history.

---

Various AI & Defense Startups — Multiple Rounds (Week Recap, Led by AI and Defense)

• What they do: Crunchbase's weekly roundup covers startups across AI infrastructure, defense autonomy, enterprise AI, and laundry-tech (an unusual entry this week)
• Investors: Mix of institutional VCs and strategic partners
• Why it matters: The pace of large-scale dealmaking picked up meaningfully this week. Beyond OpenAI's headline round, several defense tech and enterprise AI companies closed significant financings, reflecting durable investor appetite even as public software stocks remain pressured.

---

Seed Funding Market — Skewing Larger & More Competitive

• What they do: N/A — trend report on early-stage dealmaking
• Investors: N/A
• Why it matters: New Crunchbase data shows that among U.S. seed deals, only the upper bands — rounds of $10 million and above — grew in 2025, while smaller seed rounds are declining. The data, published within the past 72 hours, suggests seed-stage capital is concentrating at larger check sizes, raising the bar for first-time founders.

---

IPOs & Exits

• SpaceX: Elon Musk is preparing to allocate up to 30% of SpaceX's forthcoming IPO shares to retail investors — a sharp departure from conventional Wall Street allocation practice. The IPOX® Update (March 27) pegged SpaceX's target valuation at $75 billion for its anticipated listing. Multiple reports confirm a confidential SEC filing could come as early as this spring, with a potential June listing now assigned 47% probability by prediction markets.

• Anthropic: IPOX® Update (March 27) flagged Anthropic as eyeing a potential $60 billion U.S. debut, alongside SK Hynix and Grifols as other mega-cap listings in the pipeline. No formal S-1 has been filed as of press time.

• Kailera Therapeutics: The biopharma company filed for a U.S. IPO on Friday, March 27, 2026, according to Reuters. No deal terms were disclosed in the initial filing.

• OpenAI / SoftBank: A $40 billion SoftBank loan to OpenAI is drawing fresh analyst scrutiny as a potential signal about OpenAI's IPO timeline. Analysts are parsing the loan structure for clues about when OpenAI might pursue a public listing.

---

Investor Spotlight

• Most active VC this period: Based on coverage from the past 24–48 hours, no single firm dominated new deal announcements. The Crunchbase weekly roundup highlights broad institutional participation across AI, defense, and enterprise sectors without singling out one dominant backer. Activity from Crunchbase's "biggest rounds" tracker points toward a mix of top-tier crossover funds.

• New fund announcements: Audeo Ventures announced it exceeded its $50 million Fund target, per PR Newswire's venture capital news feed. The early-stage specialist firm confirmed it surpassed its fundraising goal.

• Emerging investors: A new VC fund focused exclusively on prediction markets launched this week with backing from Polymarket founder Shayne Coplan and Kalshi founder Tarek Mansour, among other prominent investors. Bloomberg reported on March 23 that the fund is targeting the fast-growing prediction market infrastructure space — though this falls just outside our 24-hour window, it represents a notable emerging niche gaining institutional traction.

---

Market Pulse

• Deal size trends: Mega-rounds continue to dominate headlines — OpenAI's additional $10B raise this week and SpaceX's $75B IPO target illustrate just how extreme capital concentration has become in AI and deep tech. Simultaneously, Crunchbase's fresh seed data confirms a barbell effect: large seed rounds ($10M+) are growing, while sub-$10M seeds are declining. Mid-market rounds face the most pressure.

• Investor activity: Institutional players remain highly active in AI infrastructure and defense autonomy. The week's Crunchbase roundup highlighted "a varied week for big deals" with no single sector monopolizing capital — unusual in recent quarters dominated by pure AI plays. The prediction market VC launch signals niche verticals are beginning to attract dedicated institutional capital.

• Geographic spread: U.S.-based AI and defense startups continue to command the bulk of global venture capital. However, IPOX® data notes SK Hynix (South Korea) and Grifols (Spain) are both eyeing U.S. listings — suggesting non-U.S. companies increasingly view American public markets as their preferred exit venue. Indian startup IPO pipeline also remains active, per Inc42, with 21 startups having filed DRHPs and 25 more in planning stages.

---

What to Watch

• SpaceX IPO timing: With prediction markets at 47% odds for a June listing and Elon Musk's confirmed plan to allocate 30% to retail investors, any SEC confidential filing news will be the biggest IPO story of 2026.
• Anthropic IPO preparation: Pegged at a potential $60B debut per IPOX®, watch for formal S-1 filings or underwriter appointments in the weeks ahead.
• OpenAI SoftBank loan structure: Analysts expect the $40B SoftBank loan terms to reveal clues about OpenAI's IPO timeline and valuation expectations.
• Kailera Therapeutics IPO: Fresh off its March 27 filing, deal terms and roadshow timing will emerge in coming weeks — one to watch in the biopharma IPO pipeline.
• Seed market compression: With larger seed rounds crowding out smaller raises, demo days and accelerator cohorts (Y Combinator Demo Day typically in April) will be a key gauge of whether early-stage founders are adjusting pitch expectations.